Please Wait
Applying Filters...
Menu
Xls
2D Structure
Also known as: Unii-4mod1f4enc, Ko539, Ko-539, 4mod1f4enc, 2134675-36-6, Menin-mll interaction inhibitor ko 539
Molecular Formula
C33H42F3N9O2S2
Molecular Weight
717.9  g/mol
InChI Key
BGGALFIXXQOTPY-NRFANRHFSA-N
FDA UNII
4MOD1F4ENC

Ziftomenib is an orally bioavailable inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) fusion protein, with potential antineoplastic activity. Upon oral administration, ziftomenib prevents the interaction between the two proteins menin and MLL, and thus the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth and proliferation of certain kinds of leukemia cells.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-methyl-5-[[4-[[2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-1-[(2S)-2-(4-methylsulfonylpiperazin-1-yl)propyl]indole-2-carbonitrile
2.1.2 InChI
InChI=1S/C33H42F3N9O2S2/c1-21(43-11-13-44(14-12-43)49(4,46)47)19-45-25(18-37)15-27-22(2)23(5-6-29(27)45)20-42-9-7-24(8-10-42)39-30-28-16-26(17-33(34,35)36)48-31(28)41-32(38-3)40-30/h5-6,15-16,21,24H,7-14,17,19-20H2,1-4H3,(H2,38,39,40,41)/t21-/m0/s1
2.1.3 InChI Key
BGGALFIXXQOTPY-NRFANRHFSA-N
2.1.4 Canonical SMILES
CC1=C(C=CC2=C1C=C(N2CC(C)N3CCN(CC3)S(=O)(=O)C)C#N)CN4CCC(CC4)NC5=C6C=C(SC6=NC(=N5)NC)CC(F)(F)F
2.1.5 Isomeric SMILES
CC1=C(C=CC2=C1C=C(N2C[C@H](C)N3CCN(CC3)S(=O)(=O)C)C#N)CN4CCC(CC4)NC5=C6C=C(SC6=NC(=N5)NC)CC(F)(F)F
2.2 Other Identifiers
2.2.1 UNII
4MOD1F4ENC
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Unii-4mod1f4enc

2. Ko539

3. Ko-539

4. 4mod1f4enc

5. 2134675-36-6

6. Menin-mll Interaction Inhibitor Ko 539

7. (s)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1h-indole-2-carbonitrile

8. 4-methyl-5-[[4-[[2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-1-[(2s)-2-(4-methylsulfonylpiperazin-1-yl)propyl]indole-2-carbonitrile

9. Ziftomenib [usan]

10. Ko-539;ziftomenibum

11. Ziftomenib [inn]

12. Ko 539 [who-dd]

13. Schembl20846943

14. Gtpl11680

15. Ex-a5611

16. Who 11651

17. Compound 151 [us10781218b2]

18. Hy-132001

19. Cs-0146342

20. 1h-indole-2-carbonitrile, 4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)-1-piperidinyl)methyl)-1-((2s)-2-(4-(methylsulfonyl)-1-piperazinyl)propyl)-

2.4 Create Date
2019-07-20
3 Chemical and Physical Properties
Molecular Weight 717.9 g/mol
Molecular Formula C33H42F3N9O2S2
XLogP35.6
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count14
Rotatable Bond Count10
Exact Mass717.28549845 g/mol
Monoisotopic Mass717.28549845 g/mol
Topological Polar Surface Area159 Ų
Heavy Atom Count49
Formal Charge0
Complexity1270
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1